2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3729 Rational combination strategies in myelofibrosis

Hsi-hsien Hsieh, PhD, Danny V. Jeyaraju, PhD2, Yue Ma3, Rajasekhar Suragani, PhD4, Lily J. Huang, PhD5
1 University of Texas Southwestern Medical Center, Dallas, Texas, United States
2 Bristol-Myer Squibbs, Princeton, United States
3 University of Texas Southwestern Medical Center, Dallas, Texas, United States
4 Bristol-Myer Squibbs, Cambridge, Massachusetts, United States
5 University of Texas Southwestern Medical Center, Dallas, Texas, United States

Background: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by splenomegaly, leukocytosis, and ineffective erythropoiesis. The resulting anemia is associated with poor quality of life and reduced survival. JAK inhibitors such as ruxolitinib (RUX) are standard frontline therapy but provide limited disease modification and frequently exacerbate anemia. Therefore, two distinct unmet needs persist: deeper control of the malignant clone and effective treatment of MF-associated anemia. We addressed both arms of this challenge using complementary murine models: one testing disease control with a bromodomain and extra-terminal (BET) inhibitor, the other testing anemia improvement with the erythroid maturation agent luspatercept in combination with JAK inhibitors.

Methods: MPL model study: Mutations in the thrombopoietin receptor (MPL) are recognized as key driver mutations in myelofibrosis. Murine bone marrow stem and progenitor cells were transduced with retroviruses co-expressing MPL(W515L) and GFP and transplanted into lethally irradiated recipients to induce MF. From week 2, mice received RUX or RUX plus the BET inhibitor BMS-986158. Complete blood counts (CBC) were monitored serially. Spleen weight and mutant allele burden (GFP+ variant allele frequency (VAF)) were assessed at endpoint by flow cytometry in bone marrow (BM), spleen (SP), and peripheral blood (PB). Anemia study (ACD model): anemia of inflammation/chronic disease (ACD) was induced with injections of heat-killed Brucella abortus. Near hemoglobin nadir, mice were treated with RAP-536 (murine analog of luspatercept) alone or combined with RUX or momelotinib (MMB), another JAK inhibitor. CBC and reticulocytes were measured serially.

Results: In the MPL(W515L) model, RUX combined with BMS-986158 resulted in a more rapid normalization of leukocytosis at day 7 and a 39% reduction in spleen weight at day 28 compared with RUX alone (p<0.01). However, GFP+ VAF in bone marrow (BM), spleen (SP), and peripheral blood (PB) did not differ significantly between the two arms. The deeper suppression of myeloproliferation was accompanied by progressive anemia in the combination arm, which were not observed with RUX alone. By day 28, red blood cell (RBC) count, hemoglobin (Hb), and hematocrit (HCT) were reduced by 39%, 51%, and 44%, respectively compared to RUX monotherapy group (all p<0.0001). The anemia was identified as a key liability of more intensive disease control. In the ACD model, the combination of RUX and RAP-536 significantly improved erythropoietic parameters compared to RAP-536 alone across multiple timepoints. Following 20 days of treatment, Hb increased by 30% (p<0.01) and HCT by 18% (p<0.05) with combination therapy. Erythroid benefits were also observed with the combination of RAP-536 and MMB, which produced significantly higher Hb and HCT levels than RAP-536 monotherapy after 18 days of treatment (Hb: 12.2 vs. 9.9 g/dL; HCT: 44.6% vs. 37.2%; both p<0.01). This improvement was consistent with the relief of inflammation-driven suppression of erythropoiesis and enhanced late-stage erythroid maturation.

Conclusions: These complementary studies provide a unified, mechanism-based strategy for myelofibrosis that concurrently addresses the two major clinical challenges of the disease: uncontrolled myeloproliferation and anemia. Intensifying myeloproliferative control by adding BET inhibition to RUX enhanced leukocyte normalization and spleen reduction but exacerbated anemia, highlighting the hematologic cost of deeper myelosuppression. Conversely, luspatercept-based combinations with JAK inhibitors effectively improved erythroid parameters in an inflammatory anemia model. These findings provide a strong preclinical rational for combining disease-modifying agents with erythroid-maturation therapies and support the development of luspatercept-containing combinations alongside emerging MF therapeutics. Such approaches may enable deeper disease control while preserving erythropoiesis.

Hsi-hsien Hsieh, PhD: No relevant conflicts of interest to declare.